Our novel demonstration that RasGRP4 may play a crucial role in DLBCL growth raises the exciting possibility that RasGRP4 inhibition may be a therapeutic approach in DLBCL. The gene discussed is RASGRP4; the disease is diffuse large B-cell lymphoma.